Avextra Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 58

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $10.2M

  • Investors
  • 3

Avextra General Information

Description

Developer of cannabis-based medicines designed to treat symptoms of various diseases. The company's medicines specialize in modern medical research and products that include cannabinoid extracts and active pharmaceutical ingredients for remedial healing from chronic pain, multiple sclerosis spasticity, chemotherapy-induced nausea and vomiting, and epilepsy, enabling patients suffering from untreatable diseases to get relief.

Contact Information

Website
www.avextra.com
Formerly Known As
Eurox, Eurox Group
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Kurfürstendamm 195
  • 10707 Berlin
  • Germany
+49 06251
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Vertical(s)
Cannabis, LOHAS & Wellness, Industrials, HealthTech
Corporate Office
  • Kurfürstendamm 195
  • 10707 Berlin
  • Germany
+49 06251

Avextra Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Avextra Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series B) 06-Jul-2024 $10.2M Completed Generating Revenue
5. Later Stage VC 07-Feb-2024 Completed Generating Revenue
4. Secondary Transaction - Private 11-Sep-2023 Completed Generating Revenue
3. Early Stage VC 15-Mar-2023 Completed Generating Revenue
2. Early Stage VC 06-Apr-2022 $4.84M $8.44M Completed Generating Revenue
1. Early Stage VC 05-Jul-2021 $3.6M $3.6M Completed Generating Revenue
To view Avextra’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Avextra Patents

  • 5

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 5

    Pending

  • Expiring in next 12 mo

Avextra Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202508781-D0 Cannabinoids for use in the reduction of symptom burden in pallative care patients Pending 04-Jun-2025
GB-202503576-D0 Cannabinoids for use in the treatment of chemotherapy induced neuropathic pain (cinp) Pending 12-Mar-2025
WO-2026190272-A1 Cannabinoids for use in the treatment of chemotherapy induced neuropathic pain (cinp) Pending 12-Mar-2025
GB-202503575-D0 Low dose cannabinoids for use in the treatment of sleep disorders Pending 12-Mar-2025
WO-2026190269-A1 Low dose cannabinoids for use in the treatment of sleep disorders Pending 12-Mar-2025 A61K31/658
To view Avextra’s complete patent history, request access »

Avextra Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Avextra Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
SynQube Corporation Minority
Iberis Capital Venture Capital Minority
SEED Innovations (Private Equity) Venture Capital Minority
To view Avextra’s complete investors history, request access »

Ready to get started?

Request a free trial

Avextra FAQs

  • When was Avextra founded?

    Avextra was founded in 2019.

  • Where is Avextra headquartered?

    Avextra is headquartered in Berlin, Germany.

  • What is the size of Avextra?

    Avextra has 58 total employees.

  • What industry is Avextra in?

    Avextra’s primary industry is Pharmaceuticals.

  • Is Avextra a private or public company?

    Avextra is a Private company.

  • What is Avextra’s current revenue?

    The current revenue for Avextra is .

  • How much funding has Avextra raised over time?

    Avextra has raised $72.9M.

  • Who are Avextra’s investors?

    SynQube, Iberis Capital, and SEED Innovations (Private Equity) have invested in Avextra.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process